1. Early COVID-19 XBB.1.5 Vaccine Effectiveness Against Hospitalisation Among Adults Targeted for Vaccination, VEBIS Hospital Network, Europe, October 2023-January 2024.
- Author
-
Antunes L, Mazagatos C, Martínez-Baz I, Naesens R, Borg ML, Petrović G, Fatukasi T, Jancoriene L, Machado A, Oroszi B, Husa P, Lazar M, Dürrwald R, Howard J, Melo A, Pérez-Gimeno G, Castilla J, Bernaert E, Džiugytė A, Makarić ZL, Fitzgerald M, Mickienė A, Gomez V, Túri G, Součková L, Marin A, Tolksdorf K, Nicolay N, and Rose AMC
- Subjects
- Humans, Aged, Europe epidemiology, Female, Male, Middle Aged, Adult, Case-Control Studies, Young Adult, Aged, 80 and over, Adolescent, Hospitalization statistics & numerical data, COVID-19 prevention & control, COVID-19 epidemiology, COVID-19 Vaccines immunology, COVID-19 Vaccines administration & dosage, SARS-CoV-2 immunology, Vaccine Efficacy statistics & numerical data, Vaccination statistics & numerical data
- Abstract
We conducted a multicentre test-negative case-control study covering the period from October 2023 to January 2024 among adult patients aged ≥ 18 years hospitalised with severe acute respiratory infection in Europe. We provide early estimates of the effectiveness of the newly adapted XBB.1.5 COVID-19 vaccines against PCR-confirmed SARS-CoV-2 hospitalisation. Vaccine effectiveness was 49% overall, ranging between 69% at 14-29 days and 40% at 60-105 days post vaccination. The adapted XBB.1.5 COVID-19 vaccines conferred protection against COVID-19 hospitalisation in the first 3.5 months post vaccination, with VE > 70% in older adults (≥ 65 years) up to 1 month post vaccination., (© 2024 The Author(s). Influenza and Other Respiratory Viruses published by John Wiley & Sons Ltd.)
- Published
- 2024
- Full Text
- View/download PDF